Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2014 - 2023)

Lineage Cell Therapeutics has reported Return on Invested Capital for 6 years, with the latest figure at 0.0% in Q4 2023.

• For the quarter ending Q4 2023, Return on Invested Capital changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2023 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed N/A from the prior year.
• Return on Invested Capital for Q4 2023 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.0% in Q3 2021, with the low at 0.0% in Q3 2019.
• Historically, Return on Invested Capital has averaged 0.0% across 4 years, with a median of 0.0% in 2019.
• The largest YoY upside for Return on Invested Capital was 0 bps in 2023 against a maximum downside of 0 bps in 2023.
• Lineage Cell Therapeutics' Return on Invested Capital stood at 0.0% in 2019, then surged by 89 bps to 0.0% in 2021, then sank by 504 bps to 0.0% in 2022, then plunged by 158 bps to 0.0% in 2023.
• The last three Return on Invested Capital figures came in at 0.0% (Q4 2023), 0.0% (Q3 2023), and 0.0% (Q2 2023), per Business Quant data.